Identification of <i>JAK2</i> (V617F) Mutation in Myeloproliferative Neoplasms by Using Allele Specific Polymerase Chain Reaction (AS-PCR) — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Identification of <i>JAK2</i> (V617F) Mutation in Myeloproliferative Neoplasms by Using Allele Specific Polymerase Chain Reaction (AS-PCR)
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Medical Research, Yangon, Myanmar
,
Department of Clinical Haematology, Yangon General Hospital, Ministry of Health and Sports, Nay Pyi Taw, Myanmar
1 Department of Medical Research, Yangon, Myanmar
2 Department of Medical Research, Yangon, Myanmar
3 Department of Medical Research, Yangon, Myanmar
4 Department of Medical Research, Yangon, Myanmar
5 Department of Medical Research, Yangon, Myanmar
6 Department of Medical Research, Yangon, Myanmar
7 Department of Medical Research, Yangon, Myanmar
8 Department of Medical Research, Yangon, Myanmar
9 Department of Clinical Haematology, Yangon General Hospital, Ministry of Health and Sports, Nay Pyi Taw, Myanmar
Myeloproliferative neoplasms (MPNs) are a group of clonal haematopoietic stem cell disorders characterized by the proliferation of one or more myeloid cell lineages. According to WHO classification, the Janus associated kinase 2 ( JAK 2) V617F mutation is one of the major diagnostic criteria in BCR-ABL1 negative myeloproliferative neoplasms. The aim of this study is to detect the JAK 2 (V617F) mutation in patients with myeloproliferative neoplasms to get accurate diagnosis and proper management. A total of 90 clinically diagnosed MPN patients attending to Department of Clinical Haematology, Yangon General Hospital were enrolled in this study. The mean age was 53.4 ± 14 years which ranged from 16 to 81 years old and male and female ratio was 2.4:1. The identification of JAK 2 (V617F) point mutation was found to be positive in 44/90 MPN patients (48.9%). According to MPN subtypes, the JAK 2 mutation positivity was found in 19 out of 46 polycythemia vera patients (41.3%), 17 out of 25 essential thrombocythemia patients (68%), 8 out of 15 primary myelofibrosis patients (53.3%), 0 of 4 others myeloproliferative neoplasms (0%). Confirmation of each of nine JAK 2 mutation positive and negative samples was done by Sanger sequencing. The arterial or venous thrombotic attack was found in 32/44 JAK 2 mutation positive cases (72.7%) and 12/44 JAK 2 mutation negative cases (27.3%). The association between thrombotic attack and presence of JAK 2 mutation was statistically significance with p = 0.000. The diagnosis of myeloproliferative neoplasms mainly relies on the molecular genetics according to WHO classification. The Allele specific PCR reaction is sensitive, simple test and relatively cost-effective. Therefore, the identification of JAK 2 (V617F) somatic point mutation by AS-PCR should be implemented as a routine diagnosis procedure for patients with chronic and suspected myeloproliferative neoplasms.
Jaffe, E.S., Harris, N.L., Stein, H. and Vardiman, J.W. (2001) World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon, 1-351.
Dameshek, W. (1951) Some Speculations on the Myeloproliferative Syndromes. Blood, 6, 372-375. https://doi.org/10.1182/blood.V6.4.372.372
Tefferi, A. and Vardiman, J.W. (2008) Classification and Diagnosis of Myeloproliferative Neoplasm: The 2008 WHO Diagnostic Criteria and Point of Care Algorithms. Leukemia, 22, 14-22. https://doi.org/10.1038/sj.leu.2404955
Baxter, E.J., Scott, L.M., Campbell, P.J., et al. (2005) Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders. The Lancet, 365, 1054-1061. https://doi.org/10.1016/S0140-6736(05)71142-9
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowit, Z.M.J., Porwit, A., et al. (2009) The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasm and Acute Leukaemia: Rationale and Important Changes. Blood, 114, 937-951. https://www.nejm.org/doi/full/10.1056/NEJMoa051113
Kralovics, R., Passamonti, F., Buser, A.S., et al. (2005) A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. The New England Journal of Medicine, 352, 1779-1790. https://www.nejm.org/doi/full/10.1056/NEJMoa051113 https://doi.org/10.1056/NEJMoa051113
James, C., Ugo, V., Le Couedic, J.P., et al. (2005) A Unique Clonal JAK2 Mutation Leading to Constitutive Signaling Causes Polycythaemiavera. Nature, 434, 1144-1148. https://doi.org/10.1038/nature03546
Levine, R.L., Wadleigh, M., Cools, J., et al. (2005) Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis with Myeloid Metaplasia. Cancer Cell, 7, 387-397.
Jamieson, C.H., Gotlib, J., Durocher, J.A., Chao, M.P., Mariappan, M.R., Lay, M., Jones, C., et al. (2006) The JAK2 V617F Mutation Occurs in Hematopoietic Stem Cells in Polycythemia Vera and Predisposes toward Erythroid Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 103, 6224-6229. https://doi.org/10.1073/pnas.0601462103
Kiladjian, J., Elkassar, N., Cassinat, B., et al. (2006) Essential Thrombocythemias without V617F JAK2 Mutation Are Clonal Hematopoietic Stem Cell Disorders. Leukemia, 20, 1181-1183. https://doi.org/10.1038/sj.leu.2404214
Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. and Cross, N.C.P. (2005) Widespread Occurrence of the JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. Blood, 106, 2162-2168. https://doi.org/10.1182/blood-2005-03-1320
Jones, A.V., Silver, R.T., Waghorn, K., et al. (2006) Minimal Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon Alpha. Blood, 107, 3339-3341. https://doi.org/10.1182/blood-2005-09-3917
James, C., Delhommeau, F., Marzac, C., et al. (2006) Detection of JAK2 V617F as a First Intention Diagnostic Test for Erythrocytosis. Leukemia, 20, 350-353. https://doi.org/10.1038/sj.leu.2404069
Mcclure, R., Mai, M. and Lasho, T. (2006) Validation of Two Clinically Useful Assays for Evaluation of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. Leukemia, 20, 168-171. https://doi.org/10.1038/sj.leu.2404007
Campbell, P.J., Scott, L.M., Baxter, E.J., Bench, A.J., Green, A.R. and Erber, W.N. (2006) Methods for Detection of the JAK2 V617F Mutation in Human Myeloproliferative Disorders. Methods in Molecular Medicine, 125, 253-264. https://doi.org/10.1385/1-59745-017-0:253
Grenier, T.C. (2006) Diagnostics Assays for the JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. American Journal of Clinical Pathology, 125, 651-653. https://doi.org/10.1309/NXXTGRCXD0TMA3C2
Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., Schrijver, I. and Zehnder, J.L. (2006) Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis. The Journal of Molecular Diagnostics, 8, 330-334.
Steensma D.P. (2006) JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. The Journal of Molecular Diagnostics, 8, 397-526. https://doi.org/10.2353/jmoldx.2006.060007
Kannism, S., Thongnoppakhun, W. and Auewarakul, C.U. (2009) Two-Round Allele Specific Polymerase Chain Reaction: A Simple and Highly Sensitive Method for JAK2V617F Mutation Detection. Clinica Chimica Acta, 401, 148-151. https://doi.org/10.1016/j.cca.2008.12.010
Frantz, C., Sekora, D.M., Henley, D.C., Huang, C.-K., Pan, Q., Quiglay, N.B., Gorman, E., Hubbard, R.A. and Mirzo, I. (2007) Comparative Evaluation of Three JAK2 V617F Mutation Detection Methods. American Journal of Clinical Pathology, 128, 865-874. https://doi.org/10.1309/LW7Q3739RBRMBXXP
Vainchenker, W. and Constantinescu, S.N. (2005) A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases. Hematology, American Society of Hematology Education Program, 2005, 195-200. https://doi.org/10.1182/asheducation-2005.1.195
Lieu, C.H., Wu, H.S., Hon, Y.C., Tsai, W.H., Yang, C.F., Wang, C.C., Lin, Y.C., Shih, C.H. and Hsu, H.C. (2008) Prevalence of the JAK2-V617F Mutation in Taiwanese Patients with Chronic Myeloproliferative Disorders. Internal Medicine Journal, 38, 422-426. https://doi.org/10.1111/j.1445-5994.2007.01589.x
Kim, J.T., Cho, Y.G., Choi, S.I., Lee, Y.J., Kim, H.R., Jang, S.J., et al. (2010) JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR/ABL1 Negative Myeloproliferative Neoplamsms. Korean Journal of Laboratory Medicine, 30, 567-574. https://doi.org/10.3343/kjlm.2010.30.6.567
Wong, G.C., Kam, G.L. and Koay, E.S. (2011) JAK2 Mutations in Asian Patients with Essential Thrombocythaemia. Internal Medicine Journal, 41, 191-196. https://doi.org/10.1111/j.1445-5994.2010.02199.x
Tefferi, A. and Pardanani, A. (2006) Mutation Screening for JAK2V617F: When to Order the Test and How to Interpret the Results. Leukemia Research, 30, 739-744. https://doi.org/10.1016/j.leukres.2006.01.004
Barosi, G., Bergamaschi, G., Marchetti, M., et al. (2007) JAK2 V617F Mutational Status Predict Progression to Large Splenomegaly and Leukaemic Transformation in Primary Myelofibrosis. Blood, 110, 4030-4036. https://doi.org/10.1182/blood-2007-07-099184
Lasho, T.L., Mesa, R., Gilliland, D.G. and Tefferi, A. (2005) Mutation Studies in CD3+, CD19+ and CD34+ Cell Fractions in Myeloproliferative Disorders with Homozygous JAK2V617F in Granulocytes. British Journal of Haematology, 130, 797-799. https://doi.org/10.1111/j.1365-2141.2005.05682.x
Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., et al. (2005) Definition of Subtypes of Essential Thrombocythaemia and Relation to Polycythaemia Vera Based on JAK2 V617F Mutation Status: A Prospective Study. The Lancet, 366, 1945-1953. https://doi.org/10.1016/S0140-6736(05)67785-9
Rosenthal, A. and Mesa, R.A. (2014) Janus Kinase Inhibitors for the Treatment of Myeloproliferative Neoplasms. Expert Opinion on Pharmacotherapy, 15, 1265-1276. https://doi.org/10.1517/14656566.2014.913024